Skip to main content

Table 2 Quantitatively assessments of implanted β-TCP using μ-CT

From: Topical co‐administration of zoledronate with recombinant human bone morphogenetic protein-2 can induce and maintain bone formation in the bone marrow environment

 

Group 1(Control)

Group 2(rh-BMP-2)

Group 3(ZOL)

Group 4(rh-BMP-2 + ZOL)

p value

BV/ TV (%, n = 7)

 3 weeks after implantation

21.7(17.8 to 27.1)

34.6(28.4 to 36.5)

24.3(20.2 to 28.5)

35.3(27.4 to 37.8)

<0.001

 6 weeks after implantation

23.5(21.4 to 25.0)

22.8(20.0 to 25.1)

23.0(22.5 to 30.3)

30.4(27.0 to 33.9)

<0.001

BMD (mgHA/ccm, n = 7)

 3 weeks after implantation

96.0(66.3 to 104.8)

161.5(101.2 to 201.1)

70.2(48.1 to 80.2)

170.4(102.2 to 178.2)

<0.001

 6 weeks after implantation

35.4(17.7 to 60.0)

40.0(23.8 to 52.4)

57.9(43.7 to 74.4)

109.1(80.2 to 115.4)

<0.001

  1. Median, minimum, and maximum are provided. P values indicate the statistical differences between the groups. Note: β-TCP Beta-tricalcium phosphate, rh-BMP-2 Recombinant human bone morphogenetic protein-2, ZOL Zoledronate.